Last reviewed · How we verify
NCT02825719
Ulipristal Use in Chinese Population
Phase 4 trial testing Ulipristal acetate in Fibroid in 31 participants. Terminated before completion.
31 March 2020
Quick facts
| Lead sponsor | Queen Mary Hospital, Hong Kong |
|---|---|
| Phase | Phase 4 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 31 |
| Start date | 2 December 2015 |
| Primary completion | 31 March 2020 |
| Estimated completion | 31 March 2020 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- Ulipristal acetate — full drug profile →
- Placebo pills — full drug profile →
- Ferrous sulphate — full drug profile →
- Tranexamic Acid (Tranexamic Acid) — full drug profile →
Conditions studied
- Fibroid — all drugs for Fibroid →
Sponsor
Queen Mary Hospital, Hong Kong
Who can join
18 and older, female only, with Fibroid. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Uterine leiomyomas is the commonest benign tumour of the female genital tract. It lead to menorrhagia, anaemia, pain and pressure symptoms. Due to the enlarged uterus, the use of minimal invasive surgery is limited. There is also increase risk of intraoperative blood transfusion. Ulipristal acetate (UPA) is a selective progesterone-receptor modulator (SPRM). Preoperative use of Ulipristal for 12 weeks has been shown to decrease uterine bleeding, fibroid volume, pre-operative anaemia and symptoms severity. However there is still lacking evidence in terms of long term safety and efficacy, especially in Chinese population. The aim of the present study is to evaluate the effect and safety on preoperative use of Ulipristal on fibroid.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Selective Progesterone Receptor Modulators-Mechanisms and Therapeutic Utility.
Islam MS, Afrin S, Jones SI, Segars J. · · 2020 · cited 97× · PMID 32365199 · DOI 10.1210/endrev/bnaa012 -
Progesterone Signaling and Uterine Fibroid Pathogenesis; Molecular Mechanisms and Potential Therapeutics.
Ali M, Ciebiera M, Vafaei S, Alkhrait S, et al · · 2023 · cited 30× · PMID 37190026 · DOI 10.3390/cells12081117
Verify or expand the search:
- PubMed search for NCT02825719
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ulipristal acetate
Trials testing the same drug.
- NCT05674513 — Disparities in Emergency Contraceptive Metabolism Dictate Efficacy · Phase 4 · recruiting
- NCT03186586 — Ulipristal Versus Placebo for Women With Bleeding Induced by Mirena · Phase 4 · unknown
- NCT02634437 — Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matche · Phase 1 · completed
- NCT02587000 — Adenomyosis and Ulipristal Acetate · Phase 2 · completed
Other recruiting trials for Fibroid
Currently open trials in the same condition.
- NCT06143631 — Prescription of Letrozole for Uterine Myoma · Phase 4 · recruiting
- NCT06135870 — Role of Senescent Cells in Uterine Fibroid Pathogenesis (SOUL Study) · recruiting
Other Queen Mary Hospital, Hong Kong trials
Trials by the same sponsor.
- NCT07461064 — HIFU vs Observation for LSIL of Cervix: A Randomized Controlled Trial · NA · not yet recruiting
- NCT06178471 — Safety, Feasibility and Clinical Utility of Critical Care Transesophageal Echocardiography in Hong Kong · not yet recruiting
- NCT06037356 — PUL vs TURP in BPH Patients With Urinary Retention · NA · recruiting
- NCT06643416 — Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia · Phase 3 · recruiting
- NCT06551337 — Vitamin D Replacement in Bronchiectasis · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02825719 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Queen Mary Hospital, Hong Kong
- Last refreshed: 9 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02825719.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing